Skip to main content

Table 3 Segmented regression output showing impact of RMMR on weekly statin DDDs per 1000 resident-days during pre-intervention, washout, and follow-up periods for individuals with an index date in the 6–12 months after RACF entry

From: Medicines use before and after comprehensive medicines review among residents of long-term care facilities: a retrospective cohort study

 

Received RMMR (exposed)

Did not receive an RMMR (unexposed)

Difference between exposed and unexposed

Estimate (95% CI)

p -value

Estimate (95% CI)

p -value

Estimate (95% CI)

p -value

Use at baselinea

510.4 (508.4 to 512.4)

 < 0.001

502.6 (500.3 to 504.9)

 < 0.001

7.8 (4.7 to 10.8)

 < 0.001

Pre-intervention trendb

-1.4 (-1.6 to -1.2)

 < 0.001

-1.6 (-1.9 to -1.4)

 < 0.001

0.21 (-0.14 to 0.55)

0.240

Change at start of washoutc

-1.5 (-4.0 to 1.0)

0.225

4.2 (1.3 to 7.1)

0.005

-5.7 (-9.6 to -1.9)

0.004

Trend during washout periodd

-3.7 (-4.0 to -3.5)

 < 0.001

-1.6 (-2.4 to -1.3)

 < 0.001

-2.1 (-3.0 to -1.3)

 < 0.001

Change at start of follow-upe

-12.0 (-15.7 to -8.4)

 < 0.001

-1.5 (-4.0 to 1.1)

0.257

-10.6 (-15.0 to -6.1)

 < 0.001

Follow-up trendf

-2.3 (-2.8 to -1.7)

 < 0.001

-1.7 (-1.8 to -1.7)

 < 0.001

-0.54 (-1.12 to 0.05)

0.072

  1. a Number of statin DDDs available for use per 1000 resident-days in the first week of the study (-17w) (values are predicted from the regression model)
  2. b The slope of the linear regression line (i.e., the weekly rate of change in statin DDDs/1000 days) in the pre-intervention period
  3. c The immediate step/change in statin use in the first week of the washout period (i.e., the first week after the index date)
  4. d The slope of the linear regression line (i.e., the weekly rate of change in statin DDDs/1000 days) in the washout period
  5. e The immediate step/change in statin use in the first week of the follow-up period
  6. f The slope of the linear regression line (i.e., the weekly rate of change in statin DDDs/1000 days) in the follow-up period
  7. CI confidence interval, DDD defined daily dose, RACF residential aged care facility, RMMR Residential Medication Management Review